INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) will likely be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect INmune Bio to post earnings of ($0.54) per share for the quarter.

INmune Bio Trading Up 2.2 %

INMB stock opened at $8.30 on Tuesday. INmune Bio has a 1-year low of $4.32 and a 1-year high of $12.72. The business’s 50 day simple moving average is $8.28 and its 200 day simple moving average is $6.33. The firm has a market capitalization of $220.71 million, a PE ratio of -3.81 and a beta of 1.93.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Scotiabank lifted their target price on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Tuesday, February 11th. Rodman & Renshaw assumed coverage on shares of INmune Bio in a research report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Maxim Group upped their target price on INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $22.80.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.